Kornimate/medical-research-clean huggingface dataset:
radial shockwave versus low level laser therapy in patients with chronic piriformis muscle syndrome

Conditions: Extracorporeal Shock Wave; Radial Shock Wave; Low Level Laser; Piriformis Muscle Syndrome

Summary: the study aims to compare the effects of radiation shockwave and low-level laser therapy on piriformis muscle thickness, lower extremity function, pain intensity, and hip range of motion in patients with piriformis syndrome.

low back pain affects 75%-84% of the general population in developed countries, with piriformis syndrome being more common in women. piriformis syndrome is a neuromuscular disorder caused by the compression of the sciatic nerve in the infra-piriformis canal, causing sciatic pain, tingling, and numbness. few studies have examined the effectiveness of shockwave therapy in treating piriformis syndrome, but this study aims to compare results to improve treatment outcomes, save time and money, and add value to physical therapy.

Eligibility criteria:
inclusion criteria: * sixty patients' males and females with piriformis syndrome * their age will range from 30-50 years old * body mass index will be 25 to 30 (kg/m²). * both males and females. * low back pain radiating to posterior thigh, calf and foot. * chronic piriformis syndrome due to micro trauma. * gluteal pain with or without radiation through sciatic nerve pathway. * faber test and fair test and beatty test positive. * diagnosed sub-acute and chronic piriformis syndrome. * one-sided piriformis syndrome. * tenderness over lower back, buttocks and hip joint. exclusion criteria: - piriformis syndrome due to macro trauma. * lumbo-sacral disc lesion and spinal stenosis. * lumbar spondylolisthesis. * pregnancy * recent fracture and surgery of spine, hip, knee and ankle. * baker's cyst. * degenerative disease of spine and hip. * intermittent vascular claudication. * past history of vertebral fracture and spinal surgery * spinal tuberculosis. * rheumatoid disease. * disc pathology and mechanical back pain. * presence of malignant disease.
surgical versus conservative treatment of acute mallet fingers; a randomised controlled trial

Conditions: Finger Injury

Summary: the investigators are investigating if surgical treatment of injuries to the tendon which straightens the finger tip gives a better functional outcome than treatment with a splint while the tendon heals.

the investigators will randomise patients to receive splinting of their finger while their tendon heals or have surgical intervention. surgical intervention will entail fixing the tendon with bone anchors and splinting. conservative treament involves splinting while the tendon heals. we will then monitor the functional outcome of the hand using the dash questionare over 18 months.

Eligibility criteria:
inclusion criteria: * soft tissue mallet finger * acute injury exclusion criteria: * asa 3 or above * unable to give informed consent * infection in digit affected

Keywords: soft tissue mallet finger
effect of ezetimibe plus simvastatin versus simvastatin alone on atherosclerosis in the carotid artery (enhance)(p02578)

Conditions: Atherosclerosis; Hypercholesterolemia; Hyperlipoproteinemia Type II

Summary: the purpose of the study is to determine whether ezetimibe plus simvastatin will be more effective than simvastatin alone in preventing progression of atherosclerosis of the inner layer of the carotid artery.


Eligibility criteria:
inclusion criteria: * genotype-confirmed heterozygous familial hypercholesterolemia with written documentation of the genetic diagnosis at the time of screening and ldl-c \>=210 mg/dl (5.43 mmol/l), or clinical diagnosis of heterozygous familial hypercholesterolemia, defined as ldl-c \>=210 mg/dl (5.43 mmol/l) and at least one of the following: * tendinous xanthoma * child \ 159 mg/dl (4.11 mmol/l) * has a sibling with hypercholesterolemia (ldl-c \>190 mg/dl \[4.91 mmol/l\]) and tendinous xanthoma * family history with an ldl-c value distribution pattern compatible with dominant autosomal transmission and at least one relative presenting fasting total cholesterol values \>348 mg/dl (9.0 mmol/l) after exclusion of secondary causes of dyslipidemia * ldl-c \>=210 mg/dl (5.43 mmol/l) 1 week before randomization * plasma triglyceride level \<=400 mg/dl (4.52 mmol/l) exclusion criteria: * pregnancy or any other situation, condition, or illness that, in the opinion of the investigator, may interfere with optimal participation in the study * presence of an apolipoprotein b gene mutation with confirmed absence of an ldl receptor mutation in either allele * undergoing ldl-apheresis or plasma apheresis * unsuitable plaque or artery morphology * use of certain drugs, foods, or other agents known to alter cholesterol levels or to cause pharmacokinetic interactions with either ezetimibe or simvastatin
the microbiological spectrum in acute dacryocystitis

Conditions: Dacryocystitis

Summary: acute dacryocystitis in adults can be a very painful disease and may not respond well to medical therapy. the purpose of this prospective non-randomised study is to determine the microorganisms causing acute dacryocystitis and the antibiotic sensitivities of these organisms. the study also aims to correlate the microbiological findings to the severity of clinical manifestations and evaluate the effectiveness of our current practice of aspiration and empiric systemic antibiotic therapy in treating patients with acute dacryocystitis and hence review whether there is a need to alter current management strategy.


Eligibility criteria:
inclusion criteria: * painful localised fluctuant induration just inferior to the medial canthal tendon of less than 2 weeks duration. exclusion criteria: * non-fluctuant lacrimal sac swelling * uncooperative patient * unwilling patient
comparison of cvats segmentectomy versus lobectomy for lung adenocarcinoma in situ and with microinvasion

Conditions: Non-small Cell Lung Cancer Stage I; Lung Adenocarcinoma

Summary: this is a prospective, open-label, parallel, multi-center, phase iii randomized trial to evaluate the efficacy and safety of video-assisted thoracoscopic segmentectomy versus lobectomy in treating patients with lung adenocarcinoma in situ or with microinvasion.

lobectomy has long been considered the standard procedure for early-stage lung cancer, and minimally invasive techniques have been demonstrated to be associated with superior outcomes compared with lobectomy by thoracotomy. the us of segmentectomy is under investigation for selected patients with small tumors, and the use of minimally invasive strategies is applicable as well. this nationwide, multicenter, prospective, randomized open phase iii study of cvats (complete video-assisted thoracoscopic surgery) segmentectomy versus lobectomy for stage ia non-small cell lung cancer (nsclc) patients with lung adenocarcinoma in situ or with microinvasion, is aiming to evaluate the relapse free survival and 5 year overall survival (os) rate of two types of surgery. patients are randomized to 1 of 2 treatment arms. * arm i: patients undergo cvats lobectomy. * arm ii: patients undergo cvats segmentectomy. patients will be followed up every 3 months within the first year, and annually for 5 years postoperatively.

Eligibility criteria:
inclusion criteria: preoperative criteria: peripheral non-small cell lung cancer, no larger than 2 cm in maximal diameter, no lymph node metastasis, fev1%\>50% (fev1: forced expiratory volume in 1 second); preoperative imaging:pure ground-glass or mixed ground-glass nodules (part-solid, solid areas \< 0.5cm); follow-up duration last 3 months or more, hrct (hrct: high-resolution computed tomography) lesion maximum diameter was measured three times and took the average, meet the criteria of clinical surgical indications; intraoperative criteria: histologically confirmed nsclc, adenocarcinoma in situ or with microinvasion; no prior ipsilateral thoracotomy; no prior anti-neoplastic therapy; eocg performance status 0-2; sufficient organ functions; written informed consent. exclusion criteria: active bacterial or fungous infection; simultaneous or prior (within the past 5 years) other malignant disease; interstitial pneumonitis, pulmonary fibrosis, or severe copd (copd: chronic obstructive pulmonary disease); abnormal psychosis; uncontrollable diabetes mellitus; history of severe cardiovascular disease; any condition which, in the opinion of the investigator might interfere with the evaluation of the objective.
effect of ketalar to prevent postoperative chronic pain after mastectomy

Conditions: Pain; Breast Cancer

Summary: prevalence of chronic pain after mastectomy is beyond 50% 3 months after surgery. this pain is related to a sensitization of the central nervous system through n-methyl-d-asparate (nmda) receptors. ketalar might prevent the occurrence of chronic pain by anti-nmda properties after mastectomy.


Eligibility criteria:
inclusion criteria: * mastectomy in patients 18 to 80 years old exclusion criteria: * american society of anesthesiology (asa) class \>= 3 * renal, heart or hepatic failure * allergy to ketalar * psychiatric disease * chronic antalgic treatment

Keywords: ketalar nmda mastectomy postoperative chronic pain chronic pain after mastectomy for breast cancer
analysis of the microbiome in rosacea

Conditions: Rosacea

Summary: the skin and gut microbiome of rosacea patients differs from individuals without rosacea and that the microbiome suffers from unique derangements in rosacea patients following antibiotic therapy. this study was proposed to examine microbial signatures of the skin and gut microbiome in patients with moderate to severe rosacea and to identify differences between microbe communities in patients with rosacea and volunteers without rosacea using 16s ribosomal ribonucleic acid (rrna) polymerase chain reaction (pcr) amplification, sequencing and computational phylogenetics and to assess alterations in the gut and skin microbiota of patients with moderate to severe rosacea in response to varying formulations of antimicrobial treatment.


Eligibility criteria:
inclusion criteria: * participants must be over the age of 18 years old. * participants must have a current diagnosis of moderate-to-severe erythematotelangiectatic or papulopustular rosacea or free of rosacea to serve as control. * participants must have the ability to understand and communicate with the investigator. * participants must be willing and comply with the requirements of the protocol. * participants must provide written informed consent exclusion criteria: * subjects unable to provide informed consent. * subjects with significant medical history or concurrent illness that the investigator feels are not safe for study participation. * recently treated (4 weeks for topical antibiotics/steroids/other anti- inflammatory medications on the face, 8 weeks for systemic antibiotics/steroids/other immunosuppressive agents) or current (skin) diseases that would affect clinical evaluation and skin sampling. * subjects with a history of facial surgeries and cosmetic procedures (i.e. laser therapy, resurfacing, dermal fillers, and deep chemical peels) within 6 months. * subjects with facial features (i.e. significant hair growth) that would affect clinical evaluation and skin sampling. * participants with a history of chronic gastrointestinal disease, diabetes mellitus, cardiac disease or immunodeficiency disease. * intake of proton pump inhibitors, h2 receptor antagonists, laxatives, or antidiarrheal medication, nsaids, or antacids within 2 weeks prior to enrollment. * participants with a history of major surgery of the gi tract (5 years). * participants with a known hypersensitivity to tetracyclines or doxycycline or topical ivermectin * subjects unwilling to avoid facial washing for 24 hours prior to sampling and to come to sampling visit without make-up. * subjects with known allergy to lidocaine and epinephrine. * subjects with known bleeding disorders. * subjects with a history of keloids or excessive scarring. * pregnant subjects. self-reporting will be used to determine whether a patient is pregnant

Keywords: rosacea skin microbiome gut microbiome antimicrobial therapy
the effect of low dose aspirin on the pharmacokinetics of methotrexate

Conditions: Rheumatoid Arthritis

Summary: high dose aspirin have been shown to increase the level of methotrexat in patients with rheumatoid arthritis. however, most of ra patients are not currently treated with high dose aspirin. on the other hand, they frequently receive treatment with low dose aspirin. the effect of low dose aspirin on the levels of methotrexate is not well known. therefore,the purpose of this study is to assess the effect of low dose aspirin on the levels of methotrexate.

thirty rheumatoid arthritis patients currently treated with low dose methotrexate (mtx) will participate in this study. on the day of intake of methotrexate, the patients will receive 10 mg of mtx. serum levels of mtx will be measured at time 0,30 ,90, 120 minutes, and after 12 and 24 hours. two weeks later, the patients will be recommended to take 100 mg aspirin/d during a week. the levels of mtx will be measured after a week of treatment in a way similar to a week before.

Eligibility criteria:
inclusion criteria: * rapatients treated with methotrexate exclusion criteria: * contraindication to aspirin

Keywords: methotrexate aspirin pharmacokinetics
comparison of two point-of-care devices for viscoelastic hemostasis assays

Conditions: Coagulation Disorder

Summary: this study will investigate the correlation and agreement of quantra-derived parameters with parameters reported by the rotem delta and standard laboratory tests in cardiac surgery patients. in addition the association of quantra-derived parameters with select platelet function tests will be investigated.

the quantra system is a fully integrated and automated in vitro diagnostic device which uses seer sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. the quantra qplus cartridge (previously called the surgical cartridge), was developed to monitor hemostasis during major surgical procedures in adult patients. the cartridge provides six parameters that depict the functional status of a patient's coagulation system. this single site, prospective observational study will investigate the correlation and agreement of quantra-derived parameters with parameters reported by the rotem delta and standard laboratory tests (pt, aptt, fibrinogen, platelet count) in cardiac surgery patients. as an additional exploratory study, the association of quantra-derived parameters with select platelet function tests will be investigated.

Eligibility criteria:
inclusion criteria: * subject is \>18 years * subject is undergoing elective cardiac surgery with cardiopulmonary bypass * subject is willing to participate and has signed a consent form exclusion criteria: * subject is younger than 18 years * subject has known congenital coagulopathy * subject is unable to provide written informed consent
efficacy albendazole and levamisole against sth on unguja

Conditions: Ascariasis; Trichuriasis

Summary: field epidemiological studies undertaken during 2005 in four village locations in northern unguja, zanzibar examined mothers and their pre-school aged children for helminth infections. the prevalence of ascaris lumbricoides was found to have remained relatively high despite community-wide treatment with the mass administration of albendazole (a who recommended de-wormer) in coordination with community vitamin a supplementation. one hypothesis for this is that the children and mothers had ascaris infections more tolerant to albendazole that subsequently failed to clear. it is necessary to compare the present drug efficiency of albendazole (first-line de-wormer) with levamisole (second-line de-wormer) on sth infections such patients a case-control setting to shed light on the putative resistance of local ascaris/trichuris to albendazole. in so doing, this should clarify whether there is resistance developing towards albendazole and have possible implications for introducing combination therapies of levamisole and albendazole for first line de-worming mothers and their children in the future.

the study was conducted in 10 villages on unguja island representative of urban, semi-urban and rural environments. after liaison with the local shehia (the elected community leader) mothers and their children aged between 6 months and 5 years old were invited to attend a walk-in mobile clinic. in accordance with who sample size recommendations of 30 individuals per site and to cater for drop-out/non-compliance, target enrolment was about 50 mother and child pairs at each study village. stool specimens were transported to the helmtin control laboratory unguja laboratory for visual inspection of stool consistency and presence of blood, after which a single kato-katz thick smear (41.7mg) was prepared. eggs of all sth species were counted by inspection at 100x microscopy and expressed as a tally of eggs per gram (epg). to ensure consistency of egg counts, slides were read by the same two technicians for each study village. 10 mother and child pairs found positive for ascaris and/or trichuris were randomised, by coin tossing, to receive either a single tablet of alb (400mg) or an appropriate dose of lev (2.5 mg/kg). a parasitological follow-up took place 18 days after treatment where a requested stool sample was analyzed by a single kato-katz thick smear for assessment of sth clearance. in accordance with who's 'no survey without service' all attendees were given an additional alb tablet.

Eligibility criteria:
inclusion criteria: * presently with soil-transmitted helminthiasis exclusion criteria: * absence of soil-transmitted helminthiasis

Keywords: ascariasis trichuriasis drug resistance
a study, called uv population, to learn more about the safety of the study drug ultravist, which is given to get clearer x-ray pictures, in people of different sexes, races, and from different countries/regions

Conditions: Contrast Enhanced X-ray Based Examination

Summary: this is an observational study in which patient data from the past of people who received ultravist prior to an x-ray based scan are studied. in observational studies, only observations are made without specified advice or interventions. x-ray based imaging like computed tomography or angiography is used to make pictures of the structures inside the body. these pictures are needed in various medical situations. in some x-ray tests, the patient is given a compound called "contrast agent" that is injected into the vein. it helps to create clearer pictures as it makes internal body structures easier to see. with such contrast-enhanced imaging techniques, doctors can better see certain problems. ultravist is an iodine-based contrast agent. it is also called iopromide, and it is available for doctors to give patients before they have x-ray based scans. clinical studies on the overall safety of ultravist have shown that hypersensitivity reactions (hsrs) may rarely occur. hsrs are undesirable reactions of the body's defense system (immune system) to the study drug. however, more information on hsrs is needed. the main aim of this study is to find out whether certain groups of people are more likely to have hsrs after ultravist injection than others (e.g., depending on gender, race, or country/region). to do this, researchers will collect data from people with hsrs (all ages) after contrast-enhanced x-ray scans with ultravist. these data come from four observational studies that have already been completed. participants who had hsrs will be compared with participants in these studies who had no medical problems after receiving ultravist to learn more about the characteristics of people at higher risk. data will be from the year 1999 up to 2011. no visits or tests are required as part of this study.


Eligibility criteria:
inclusion criteria: * patients of all age groups which were referred to any iodine-based contrast-enhanced procedure after administration of either ultravist 300 mg i/ml or 370 mg i/ml.

Keywords: hypersensitivity reaction ct angiography contrast enhancement computed tomography
the effect of low intensity shock wave therapy for ed in pde5i non responders

Conditions: Erectile Dysfunction

Summary: low intensity shock wave therapy (li-eswt) was shown to have a beneficial effect on ed patients responding to pde5i's. this study aimed to determine the capability of swt to convert pde5 inhibitor non responders to sexually functioning males under pde5i therapy.

we included severe ed patients (60% diabetic, 85% with cardiovascular disease) that failed to respond to pde5i therapy, who scored 0-2 on the rigidity scale (rs) during pde5i therapy.treatment included 2 sessions/week for 3 weeks, repeated after a 3-week no-treatment interval. at each session li-eswt was applied on the penile shaft and crus for 3 minutes in 5 different penile anatomical sites (intensity of 0.09 mj/mm2, 300 shocks/site). one-month after end of treatment the same baseline assessment was repeated. an active pde5i medication regime was then provided and final erectile function was reassessed. main endpoints for success were changes in rs and in the international index of erectile function (iief-ed) domain score. we found that li-eswt can effectively treat severe ed patients who failed pde5i therapy. this study further emphasises the physiological effect that li-eswt can have on the erectile mechanism.

Eligibility criteria:
inclusion criteria: * ed of more than 6 months * rigidity score ≤ 2 during pde5i therapy * stable heterosexual relationship for more than 3 months * patients need to know and to agree that the study protocol does not allow any pde5i therapy till week 13 . exclusion criteria: * prior surgery or radiotherapy in pelvic region * any unstable, psychiatric, spinal cord injury and penile anatomical abnormalities * clinically significant chronic hematological disease * anti-androgens, oral or injectable androgens * cardiovascular conditions that prevent sexual activity

Keywords: li-eswt erectile dysfunction non pde5 inhibitor responders shock wave
long-term effect of tdcs in patients with disorders of consciousness

Conditions: Disorder of Consciousness

Summary: in this multicentric double-blind sham controlled study, the investigators plan to assess the effects of 20 sessions of tdcs on long-term behavioral recovery in patients with disorders of consciousness. neurophysiological outcomes (eeg) will also be collected. this research will 1) determine whether long-term behavioral recovery can be promoted with tdcs and 2) generate knowledge regarding the impact of tdcs on neurophysiological outcome (i.e., eeg) in severely brain injured patients. the investigators will compare the effects of active and sham tdcs on behavioral assessments and quantitative eeg in patients with severe brain injury and its potential application in rehabilitation.


Eligibility criteria:
inclusion criteria: * cns medication stable for at least a week * stable diagnosis (no diagnosis change based on 2 crs-r performed within 1 week). * between 3 and 24 months post injury * structural mri or ct-scan (to evidence focal lesions on the left dlpfc) exclusion criteria: * craniotomies encompassing the frontal region (electrodes location) * vps under the stimulated area (prefrontal cortex) * pacemaker * metallic cerebral implant * severe medical conditions that might influence clinical diagnosis and eeg activity (e.g., severe hepatic insufficiency or renal failure, or sub-continuous or abundant epileptiform discharges on standard eeg recordings).